C 2

limited amounts of progenitor cells recovered, and delays in immune reconstitution (resulting in infectious complications in the post transplant period).

Page 2, replace the paragraph beginning on line 15 as follows:

g. 3

The aims of the invention are achieved by a cell composition containing macrophages, myeloid cells and progenitor cells, with said progenitor cells being preferably present in a mean ratio of at least about 1%, preferably about 0.1 to 20%, with said myeloid cells being preferably present in an amount of about 10% to about 30%, with said macrophages being preferably in an amount of about 10 to about 70%, these percentages being expressed with respect to the total number of cells.

Page 2, replace the paragraph beginning on line 22 as follows:

K

--Macrophages, myeloid cells and progenitor cells are defined as CD14 $^+$  and CD64 $^+$  cells (macrophages), CD33 $^+$  cells (myeloid cells) and CD34 $^+$  cells and/or GM-CFU (progenitor cells). GM-CFU are cells able to form colonies of granulocyte and macrophage in cytokine containing semi-solid culture medium after 14 days of culture. $\hbar$ 

## KLEIN et al. S.N. 09/890,652

Page 3, replace the paragraph beginning on line 5 as follows:

/ inv

--According to an advantageous embodiment of the invention, the progenitor cells contain from about 0.1 to about 20% of stem cells, expressed with respect to the total number of progenitor cells.--

Page 3, replace the paragraph beginning on line 10 as follows:

CY

According to an advantageous embodiment, the progenitor cells are generated from and possibly included in peripheral blood mononuclear cells, and in particular are chosen among:

myelo-erythroid progenitor cells, myeloid progenitor cells, lymphoid progenitor cells or a mixture thereof.

Page 3 replace the paragraph beginning on line 20 as follows:

C1

The the cell composition of the invention, the macrophages, myeloid cells and the lymphocytes if present, are included in/or generated from blood mononuclear cells.  $\hat{t}$ -

KLEIN et al. S.N. 09/890,652

Page 4, replace the paragraph beginning on line 3, as follows:

c 8

Page 4, replace the paragraph beginning on line 9 as follows:

0.9

The invention also relates to a process for the preparation of a cell composition containing macrophages, myeloid cells and progenitor cells, with said progenitor cells being preferably present in an amount of about 0.1% to about 10%, with said macrophages being preferably in an amount of about 10 to about 60%, these percentages being expressed with respect to the total number of cells, comprising the step of mobilization of the progenitor cells in the blood of a patient, for instance by premedication of said patient with G-CSF and/or GM-CSF, or G-CSF and cyclophophosphamide, thus increasing the amount of progenitor cells in peripheral blood.

Page 4, replace the paragraph beginning on line 21 as

follows:

The process of the invention can comprise an additional step of coculture of the blood mononuclear cells and progenitors, after washing off the platelets, the granulocytes and erythrocytes, for about 4 to about 10 days, in a medium allowing differentiation of monocytes into macrophages and myeloid progenitors into polynuclear cells.

Page 5, replace the paragraph beginning on line 8 as follows:

After ex vivo differentiation and expansion contains stem cells, progenitor cells, myeloid cells, T lymphocytes and differentiated macrophages which are activated (for example by Y interferon) at the end of the process. The coculture for 3 to 12 days performed at 37°C in non adherent bags and defined medium (IMDM basis) allows increased recovery of CD34<sup>+</sup> cells and/or of intermediate hematopoietic progenitor cells. This means that normal hematopoietic progenitors are not only spared by activated macrophages, but are also stimulated to greater proliferation and differentiation.

0,11